PTU - Polskie Towarzystwo Urologiczne
list of articles:

Aspects of testosterone use in aging men
Article published in Urologia Polska 2002/55/4.

authors

Andrzej Łęcki
Poradnia Urologiczna Polikliniki Centralnego Szpitala Klinicznego Wojskowej Akademii Medycznej w Warszawie Kierownik polikliniki: lek. med. Włodzimierz KuĽma

keywords

man, aging, testosterone

summary

Our knowledge of potential benefit and risk of the testosterone replacement therapy (TRT) in men has been significantly improve during the last decade. TRT may increase muscle mass, as well as may decrease fat mass, however important changes of the force and improved function has not been demonstrated. A beneficial influence of TRT on osseous mineralization and decreasing risk of bone fractures is also unknown. In individual cases improvement of patients mood and libido has been observed. Hormonotherapy using no more than 3 years is relatively safe and adverse events such as sleep apnoea or polycythaemia may be treated with good results. Future multiccntcr clinical studies are needed to estimate a relationship between TRT and cardiovascular disorders (e.g. apoplexy or myocardial infarction) or prostate diseases.

references

  1. 1. Vermeulen A: Clinical Review 24: Androgens in the aging male. J Clin Endocrinol Melab 1991; 73: 221-224.
  2. 2. Harman SM, Mctter EJ, Tobin JD: Longitudinal effects of aging on serum total and free testosteron in healthy men. J Clin Endocrinol Melab 2001; 86: 724-731.
  3. 3. Tenover JL: Male hormone replacement therapy including andropause. Endocrinol Melab Clin North Am 1998:27; 969-987.
  4. 4. Forbes GB, Rcina JC: Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970:19; 653-663.
  5. 5. Gary A, Berlin JA, McKinlay J: An examination of research design effects on the association of testosterone and male ageing: results of a meta-analysis. J Clin Epidemiol 1994; 44: 671-684.
  6. 6. Tenover JS: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992: 75; 1092-1098.
  7. 7. Morley JE, Perry HM, Kaiser FE: Effects of testosterone replacementtherapy in hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41:149-152.
  8. 8. Sih R, Morley JE, Kaiser FE: Testosterone replacement in olderhypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-1667.
  9. 9. Barret-Connor E, Von Muhlen DG, Kritz-Silverstcin D: Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573-577.
  10. 10. Hajjar RR, Kaiser RE, Morley JE: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793-3796.
  11. 11. Philips GB, Pinkernell BH, Jing TY: The association of hypotestosteronemia with coronaty artery disease in men. Artcriosclcr Thromb 1994; 14: 701-706.
  12. 12. Webb CM, Adamson DL, de Zeigler D:Effect of acute testosterone on myocardial ischemia in men with coronary arteiy disease. Am J Cardiol 1999; 83:437-439.
  13. 13. Webb CM, McNeill JG, Hayward CS:Effects of testosterone on coronaty vasomotor regulation in men with coronary heart disease. Circulation 1999; 100:1690-1696.
  14. 14. Crook D: Androgens and the risk of cardiovascular disease. Aging Male 2000; 3:190-195.
  15. 15. Orwoll ES, Klein RF: Osteoporosis in men. Endocr Rev 1995; 16: 87-116.
  16. 16. Jackson JA, Riggs MW. Spiekerman AM:Testosterone deficiency as a risk factor for hipfractures in men: a case-control study. Am J Med Sci 1992; 304: 4-8.
  17. 17. Goldray D, Wcisman Y, Jaccard N:Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl. J Clin Endocrinol Metab 1993; 76: 288-290.
  18. 18. Snyder PJ, Peachey H, Hannoush P:Effect of \\\\\\\'testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.
  19. 19. Behre HM, Kliesh S, Lcifkc E:Long-term efeel of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-2390.
  20. 20. Marin P, Holmang S, Gustafsson C:Androgen treatment of abdominally obese men. Obesity Res 1993; 1: 245-251.
  21. 21. Matsumoto AM, Sandblom RE, Schocnc RB: Testosterone replacement in hypogonadal men: effects of obstructive sleep apnoea, respiratory drives and sleep. Clin Endocrinol 1985; 22:713-721.
  22. 22. Santamaria JD, Prior JC, Flectham JA: Reversible reproductive dysfunction in men with obstructive sleep apnea. Clin Endocrinol 1988; 28:461-470.
  23. 23. Krauss DJ, Taub HA, Lantinga LJ:Risks of blood changes in hypogonadal men treated with testosterone enanthate for erectile dysfunction. J Urol 1991; 146: 1566-1570.

correspondence

Andrzej Łęcki
ul. Sosnowiecka 4/4
02-496 Warszawa
tel.: 0-503 92 65 90